(firstQuint)A Study of Sativex for Relief of Spasticity in Subjects With Multiple Sclerosis.

.

 This was an eight week (two weeks baseline, six weeks treatment), multicentre, double blind, randomised, placebo controlled parallel group study to evaluate the efficacy, safety and tolerability of Sativex(R) in subjects diagnosed with MS and spasticity.

 Subjects were screened to determine eligibility and completed a two week baseline period.

 Subjects then returned to the site for assessment, randomisation and dose introduction.

 Visits occurred at the end of treatment week two and at the end of the study (treatment week six) or withdrawal.

.

 A Study of Sativex for Relief of Spasticity in Subjects With Multiple Sclerosis.

@highlight

The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex(R) in subjects diagnosed with MS and spasticity.

